This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Reports Development Of Improved Cancer Immunotherapy At The 2014 Annual Meeting Of The American Society Of Clinical Oncology

-- T-cell Redirecting Immunotherapy Enhanced With Interferon-α in Human Pancreatic and Gastric Cancer Models --

CHICAGO, June 1, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported the development of bispecific antibodies that redirect human T-cells to certain solid cancers.

T-cell redirected therapy of cancer is one of several new methods of cancer immunotherapy being studied both clinically and preclinically. In contrast to hematological tumors, little progress has been made in this approach to treat the more challenging solid cancers, including pancreatic and gastric cancers, two malignancies with very high rates of mortality.

The Company has previously reported the development of (E1)-3s, a novel investigational T-cell redirecting bispecific antibody created using the Company's patented DOCK-AND-LOCK™ protein conjugation technology, for the potential treatment of pancreatic and gastric cancers. These and various other solid cancers express high-levels of TROP-2, a target recognized by the bispecific (E1)-3s, which also binds to the CD3 antigen on T cells. (E1)-3s has previously been shown to effectively induce a potent and specific T-cell-mediated killing of human pancreatic and gastric cancer cell lines. For more information on (E1)-3s, please refer to the Company's press release at

In the current study, the effect of interferon-α (IFN-α), which has demonstrated clinical efficacy in multiple solid cancers, on the T-cell redirecting bispecific antibody was evaluated using animal models of human pancreatic or gastric cancer. In the gastric cancer model, treatment with a combination of IFN-α and (E1)-3s bispecific antibody was superior to the bispecific antibody alone ( p=0.0007) in delaying the out-growth of tumor. The combination also significantly delayed tumor growth in the pancreatic cancer model compared to all other treatment groups ( p<0.0007), including the IFN-α only treatment group.

"We believe this is the first report of enhancing T-cell redirected cancer immunotherapy with an immunomodulatory cytokine, such as interferon," remarked Ms. Sullivan. "The challenge with this technology is to translate promising clinical effects found in leukemia and lymphomas to the more resistant solid cancers, and we have chosen to study two of the most lethal cancers, pancreatic and gastric cancers," she added.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs